Trial Profile
A neo-adjuvant, phase I/II trial of TG-4010 in early stage, non-small cell lung cancer patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 18 Dec 2019
Price :
$35
*
At a glance
- Drugs TG 4010 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Dec 2019 According to a Transgene media release, status changed from planning to withdrawn prior to enrolment, as company has taken the decision to stop further development of TG4010.
- 15 Mar 2016 New trial record
- 08 Mar 2016 According to a Transgene media release, this trial is expected to be initiated in 2016.